Dr. Yan Pangke has been deeply involved in the research and development of innovative drugs for nearly 20 years and is currently the General Manager of Hisilicon Pharmaceutical Group. Adhering to national strategies and clinical needs, focusing on anesthesia and analgesia, chronic disease metabolism, respiratory system, and oncology fields, I have led and participated in over 20 national and provincial-level scientific research projects.
Dr. Yan has published a total of 43 high-level papers, obtained 62 authorized invention patents at home and abroad, and has been awarded the titles of Sichuan Province Distinguished Expert, Sichuan Province Outstanding Entrepreneur, Chengdu City Distinguished Expert, and Chengdu May Day Labor Medal. He led the R&D team to successfully promote the approval and inclusion of four innovative Class 1 drugs in medical insurance. The core product, epoxicol, broke the long-term monopoly of imported intravenous anesthetics and was recently approved for market by the US FDA; Actively promoting the internationalization of pharmaceuticals, we have recently achieved external authorization cooperation with a potential total transaction amount exceeding 6 billion US dollars.